An oral formulation of gold for the treatment of rheumatoid arthritis.
Twenty-two patients with active rheumatoid arthritis were entered into a trial during which an oral gold formulation was administered at two dosages (4 mg/d and 6 mg/d) for 12 weeks. Seventeen patients completed the trial. Both dosages produced a similar improvement in the indices of inflammation. Five patients were not benefited by the treatment, adverse side-effects were reported in 10 and 5 were withdrawn from the trial.
D000284:Administration, Oral; D000328:Adult; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001310:Auranofin; D006051:Aurothioglucose / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002986:Clinical Trials as Topic; D005260:Female; D006046:Gold / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000097:blood; D006801:Humans; D007596:Joints / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010720:Phosphines / Q000008:administration & dosage
D010720:Phosphines; D006051:Aurothioglucose; D001310:Auranofin; D006046:Gold